Lundbeck announced the start of a phase II clinical study to assess Lu AG09222 for migraine prevention
The HOPE study, a clinical phase II study, will assess the efficacy, safety, and tolerability of Lu AG09222 in migraine prevention.H. Lundbeck A/S (Lundbeck) announced that it has expanded its clinical mid-stage pipeline with the initiation of the HOPE study, a randomized, double-blind, phase II, proof of concept, study to assess efficacy, safety, and tolerability of Lu AG09222 as a treatment for the prevention of migraine. Lu AG09222 is an investigational monoclonal antibody (mAb) that is designed to bind and inhibit signaling mediated by pituitary adenylate cyclase-activating polypeptide (